REMS for new biologic; CMO pair seeks high-volume orders;

> The FDA has required a risk evaluation and mitigation strategy for Xiaflex, the recently approved biologic from Auxilium Pharmaceuticals. Item

> A collaboration between Albemarle Corp. and PharmaCore aims to handle projects that require high-volume capacity. Release

> East African nations are considering counterfeit-drug legislation that threatens generics--to India's dismay. Article

> Formatech is celebrating the issuance of U.S. patent 7,659,310, "Methods of Enhancing Solubility of Agents," which covers novel formulation methods for hydrophobic compounds. Release

> The $20-million Abacus Parenteral Drug facility in Mukono, Uganda, is up and running, yielding cheaper drugs and displacing imports from Europe and India. Article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.